Tuohong medicine will cooperate with Jiangsu Provincial People's hospital to develop anti-tumor, anti-virus and other immune cell treatment technologies

Jiangsu tuohong Pharmaceutical Co., Ltd will work with Jiangsu People's hospital to develop anti-tumor, anti-virus and other immune cell treatment technologies, and develop affordable new anti-cancer drugs "Antineoplastic drugs are expensive because most of the new anti-cancer drugs under patent protection have to be imported." The head of the company said that at present, almost all new anti-cancer drugs in China are generic drugs, and the price of imported anti-cancer drugs will not fall naturally The oncology department of the provincial people's hospital has obtained the tumor professional qualification certification of the national drug clinical trial institution, and is currently undertaking dozens of clinical verification tasks of new tumor drugs After cooperation with the company, it plans to invest 30 million yuan in pathological research At present, the two buildings specially used for research and development have entered the internal decoration stage, some of the equipment has been in place, and will be installed and debugged, and then enter the drug research and development and production stage, and apply to the state for drug production quality management standard certification It is reported that in addition to the research and development of new anti-cancer drugs, the company will also build four research platforms, including genetic engineering drugs and monoclonal antibody drugs, peptide drugs, targeted emulsion drugs, and plant tissue cell culture research and development, forming a "production, learning and research" one-stop industrial chain, and building a world-class antibody pharmaceutical enterprise.